#Cancer Research #Switzerland #ADC Therapeutics #Lausanne #ADCT-242

ADC Therapeutics Unveils Promising Preclinical Results at AACR 2025 Annual Meeting

In an exciting development for cancer research, ADC Therapeutics SA, a leader in the field of antibody-drug conjugates (ADCs), revealed significant preclinical findings during the American Association for Cancer Research (AACR) Annual Meeting 2025. The research highlighted the efficacy of their innovative ADCs targeting Claudin-6, prostate-specific membrane antigen (PSMA), and alanine, serine, cysteine transporter 2 (ASCT2). The data suggest these novel therapies could offer hope for patients with solid tumors and hematologic malignancies.

Key Highlights from the Presentations

Patrick van Berkel, PhD, Chief Scientific Officer of ADC Therapeutics, emphasized the promising potential of their exatecan-based ADCs, suggesting they could effectively treat a wide range of cancers beyond just lymphoma. In particular, the oral presentation focused on ADCT-242, a groundbreaking ADC targeting Claudin-6, which exhibited impressive antitumor activity.

Key findings for ADCT-242 included:

• - Potent anti-tumor effects in vivo, demonstrated through PA-1 and OVCAR-3 xenograft models exhibiting medium CLDN6 expression.
• - Validation of Claudin-6-dependent anti-tumor activity in lung cancer models derived from patient tumors.
• - Favorable tolerance profile, with no significant adverse effects noted in both mice and cynomolgus monkeys at doses reaching 150 mg/kg and 40 mg/kg, respectively.

In conjunction with the oral presentation, poster sessions showcased additional promising preclinical data on their other investigational ADCs targeting PSMA and ASCT2. The data for ADCT-241, a novel PSMA-targeting ADC, revealed its effective antitumor action in both xenograft studies and patient-derived prostate cancer models, showcasing its potential in combination treatments alongside enzalutamide. Additionally, ADCT-241 was reported to be well tolerated in both rat and cynomolgus monkey models.

The ASCT2-targeting ADC, HuB14-VA-PL2202, also revealed promising results during its presentation. This ADC demonstrated strong in vitro and in vivo antitumor activities against ASCT2-positive solid and hematologic cancer cell lines, with satisfactory tolerance observed in cynomolgus monkey studies.

The Future of ADC Therapeutics

The demonstration of these results at AACR 2025 exemplifies ADC Therapeutics’ commitment to transforming the treatment landscape for various cancers. With their pioneering approach to ADC technology, the company is setting the stage for the next generation of personalized cancer therapies.

As they continue their journey of innovation, ADC Therapeutics not only aims to expand the therapeutic applications of ADCs but also hopes to improve the outcomes for patients battling complex and difficult-to-treat cancers. Their promising data fuels optimism within the oncology community and among patients seeking new avenues for treatment.

About ADC Therapeutics

ADC Therapeutics, headquartered in Lausanne, Switzerland, is recognized globally for its innovative work in developing ADCs. Their flagship product, ZYNLONTA (loncastuximab tesirine-lpyl), has received accelerated approval by the FDA for the treatment of certain types of lymphoma, underscoring their role in advancing cancer therapies. The company embodies a commitment to research that could not only change treatment paradigms but also provide hope to patients worldwide.

To learn more about their latest findings and technology advancements, visit ADC Therapeutics’ website.

Conclusion

The presentations at AACR 2025 exemplifying strong preclinical activity for ADC Therapeutics’ products signal potential breakthroughs in cancer treatment strategies. With ongoing research and development, the quest to enhance treatment efficacy and safety continues, inspiring hope in the ever-evolving fight against cancer.